A phase II trial for mogamulizumab conducted in Japan identified an ORR of 34% in their cohort of patients with R/R CCR-positive PTCL, inclusive of PTCL-NOS (n = 16), AITL (n = 12) and ALK-negative ALCL (n = 1). The gene discussed is ALK; the disease is anaplastic large cell lymphoma.